Clincosm LogoSign in Get a demo

COVID-19 Associated Coagulopathy in Egypt

Sponsor
Assiut University (Other)
Overall Status
Completed
CT.gov ID
NCT04507230
Collaborator
(none)
106
Enrollment
1
Location
2.8
Actual Duration (Months)
38
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Coagulopathy is one of the most significant prognostic factors in patients with COVID-19 and is associated with increased mortality and admission to critical care. Most commonly observed coagulopathy in patients hospitalized with COVID-19 (COVID-19-associated coagulopathy) is characterized by increased D-dimer and fibrinogen levels. 71% of patients who did not survive hospitalization reported to have developed disseminated intravascular coagulation (DIC) compared to 0.6% of survivors.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    studying the detailed coagulation screen and second line coagulation parameters including both thrombophilia screen and other acute phase coagulation factors.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    106 participants
    Observational Model:
    Cohort
    Time Perspective:
    Cross-Sectional
    Official Title:
    Assessment of COVID-19 Associated Coagulopathy and Hypercoagulable State in Upper Egypt
    Actual Study Start Date :
    Aug 7, 2020
    Actual Primary Completion Date :
    Oct 31, 2020
    Actual Study Completion Date :
    Oct 31, 2020

    Outcome Measures

    Primary Outcome Measures

    1. Coagulation screen [1 month]

      Full coagulation screen

    2. Thrombophilia screen [1 month]

      Full thrombophilia screen

    3. VWF, FVIII [1 month]

      VWFAg, FVIII

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • patients with COVID 19 positive by RT- PCR
    Exclusion Criteria:
    • no exclusions

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Assiut University Hospitals Assiut Egypt 71515

    Sponsors and Collaborators

    • Assiut University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    Azza Abdelaal, lecturer of clinical pathology, Assiut University
    ClinicalTrials.gov Identifier:
    NCT04507230
    Other Study ID Numbers:
    • 17300413
    First Posted:
    Aug 11, 2020
    Last Update Posted:
    Mar 11, 2021
    Last Verified:
    Mar 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Azza Abdelaal, lecturer of clinical pathology, Assiut University
    hypercoagulable
    COVID-19
    Additional relevant MeSH terms:
    COVID-19
    Hemostatic Disorders
    Blood Coagulation Disorders

    Study Results

    No Results Posted as of Mar 11, 2021